- Home
- RAPP vs INBX Comparison
RAPP vs INBX Comparison
Compare RAPP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPP
- INBX
- Stock Information
- Founded
- RAPP 2022
- INBX 2010
- Country
- RAPP United States
- INBX United States
- Employees
- RAPP N/A
- INBX N/A
- Industry
- RAPP
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RAPP
- INBX Health Care
- Exchange
- RAPP Nasdaq
- INBX Nasdaq
- Market Cap
- RAPP 439.4M
- INBX 430.2M
- IPO Year
- RAPP 2024
- INBX 2020
- Fundamental
- Price
- RAPP $26.59
- INBX $33.88
- Analyst Decision
- RAPP Strong Buy
- INBX Hold
- Analyst Count
- RAPP 4
- INBX 2
- Target Price
- RAPP $37.00
- INBX N/A
- AVG Volume (30 Days)
- RAPP 1.1M
- INBX 123.8K
- Earning Date
- RAPP 11-06-2025
- INBX 11-13-2025
- Dividend Yield
- RAPP N/A
- INBX N/A
- EPS Growth
- RAPP N/A
- INBX N/A
- EPS
- RAPP N/A
- INBX N/A
- Revenue
- RAPP N/A
- INBX $1,400,000.00
- Revenue This Year
- RAPP N/A
- INBX $563.00
- Revenue Next Year
- RAPP N/A
- INBX $230.77
- P/E Ratio
- RAPP N/A
- INBX N/A
- Revenue Growth
- RAPP N/A
- INBX N/A
- 52 Week Low
- RAPP $6.43
- INBX $10.81
- 52 Week High
- RAPP $42.27
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- RAPP 55.67
- INBX 70.20
- Support Level
- RAPP $26.05
- INBX $31.75
- Resistance Level
- RAPP $30.67
- INBX $37.53
- Average True Range (ATR)
- RAPP 2.04
- INBX 1.99
- MACD
- RAPP -0.34
- INBX 0.27
- Stochastic Oscillator
- RAPP 32.21
- INBX 67.38
About RAPP Rapport Therapeutics Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.